Slide 1: 2013 First quarter results
2013 First quarter results 9 MAY 2013
Slide 2: First quarter 2013 highlights
First quarter 2013 highlights • Revenue € 244,6 million, up 11,4%. • EBITDA € 61,3 million or 25,1% of sales, up 13,5% • Operating income (EBIT) € 52,6 million or 21.5% of sales, up 10,5% • Net income € 37,8 million or 15.4% of sales, up 11,8% • Successful conclusion of the acquisition of a portfoli
Slide 3: Main product sales
Main product sales Corporate products including orphan drugs now account for 44,6% of revenue (million Euro) 1Q 2013 1Q 2012 Change % Zanidip® (lercanidipine) 31.8 31.3 1.4 Zanipress® (lercanidipine+enalapril) 14.1 12.4 13.5 Urorec® (silodosin) 10.4 7.6 36.7 Livazo® (pitavastatin) 5.9 3.1 88.8 Other
Slide 4: A richer product portfolio
A richer product portfolio Orphan drugs 11.7% Other corporate products 6.1% OTC 17,7% Livazo 2.4% Urorec 4.2% Zanipress 5.8% Zanidip 13.0% Subsidiaries’ local product portfolios 34.8% Pharmaceutical chemicals 3.6% Other revenue 0.7% Data: First quarter 2013 Total revenue € 244.6 m 4
Slide 5: Composition of revenue: New markets and new products drive growth
Composition of revenue New markets and new products drive growth (million Euro) 1Q 2013 1Q 2012 Change % Italy 62.6 62.6 0.0 France 29.4 32.2 (8.6) Russia and other CIS countries 24.6 13.0 89.7 Germany 18.2 16.1 12.7 Turkey 17.8 15.6 14.2 U.S.A. 10.1 1.2 n.s. Portugal 7.8 8.6 (9.6) Spain 7.5 8.9 (15
Slide 6: A growing presence in Eastern Europe and Turkey
A growing presence in Eastern Europe and Turkey Russia and other CIS 10.4% Germany 7.7% France 12.5% Turkey 7.6% USA 4.3% Portugal 3.3% Italy 26.5% Spain 3.2% Other W. Europe countries 2.8% Other CEE 3.5% Other international sales 18.2% (sales to licensees and exports) Data: First quarter 2013 Pharm
Slide 7: First quarter 2013 results: Significant sales and earnings growth
First quarter 2013 results Significant sales and earnings growth (million Euro) 1Q 2013 1Q 2012 Change % Revenue 244.6 219.6 11.4 Gross Profit 159.2 141.6 12.5 as % of revenue 65.1 64.5 SG&A Expenses 87.1 77.3 12.7 as % of revenue 35.6 35.2 R&D Expenses 18.5 15.7 17.4 as % of revenue 7.6 7.2 Other I
Slide 8: Financial position and Shareholders' equity
Financial position and Shareholders’ equity (million Euro) 31 Mar 2013 31 Dec 2012 Change Cash and short-term financial 50.7 38.4 12.3 investments Bank overdrafts and short-term loans (107.1) (56.0) (51.1) Loans – due within one year (8.2) (8.1) (0.1) Loans – due after one year (127.8) (127.7) (0.1)
Slide 9: Financial projections: 2013 targets and plan for 2015
Financial projections 2013 targets and plan for 2015 2012 2013 2015 (million Euro) Actual Targets Plan Revenue 828.3 ̴ 930 1,025 -1,075 Operating income 167.0 ̴ 190 210 - 220 (EBIT) Net Income 118.5 ̴132 140 - 150 9
Slide 10: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finan